Background: Diagnosing typhoid fever definitively, using bone-marrow, blood or feces culture is either invasive, timeconsuming, expensive, or complicated. Hence, clinicians often use clinical presentations and/or rapid diagnostic methods to examine the indirect evidence of Salmonella typhi infections. This study describes the proportion of typhoid fever, challenges of diagnosing typhoid fever, and the kinetics of anti-Salmonella O9 IgM. Methods: During a prospective dengue study in Bandung, Indonesia, 1,431 febrile occurrences were observed among 2,978 adult volunteers over a four-year period. As typhoid fever is endemic and represents a major cause of febrile illness in this study area, acute-and convalescent-phase sera from 964 subjects that had been excluded for dengue and chikungunya infections, were tested with Tubex ® TF. To observe the kinetics of anti-Salmonella O9 IgM, we tested sequential sera up to 260 days post-illness from 3 subjects. Results: Based on Tubex ® TF, 71 of 964 (7.4%) subjects had anti-Salmonella O9 IgM (score≥4) in their convalescent sera. Anti-Salmonella O9 IgM scores in convalescent sera increased compared to the acute sera in 36 subjects, indicating probable acute typhoid fever. The convalescent scores decreased/remained the same as acute sera in the other 35 subjects, which more likely indicating previous S. typhi infections. Using serially collected sera, it was determined that anti-Salmonella O9 IgM could be detected for a long period after illness. Conclusion: Tubex ® TF test should be conducted using paired acute-and convalescent-phase sera to reduce the chance of false positive result that may be due to long-lasting anti-Salmonella O9 IgM.
Background: Blastocystis hominis is an intestinal parasite that can induce both intra- and extraintestinal symptoms. This article aims to describe the symptom findings in cases of HIV children co-infected with B. hominis. Case Presentation: A 3-year-old boy with HIV/AIDS came with diarrhea and skin rashes. The direct smear technique, formalin-ethyl acetate concentration technique, Jones medium culture, and trichrome staining were all used to investigate a single stool specimen from this patient. The results of the examination showed B. hominis infection with intensity <5/high power field (HPF). Extraintestinal symptoms such as skin rashes were not seen in this patient after appropriate treatment. Conclusion: B. hominis infection can cause extraintestinal symptoms such as a red rash on the skin. When a patient presents with a skin rash of unknown origin, having their stool tested for parasites is a concern.
Antiviral drug therapies have been utilized to prevent disease progression in patients positive HIV-1. Various research has been conducted to investigate and develop a potential functional therapy to suppress HIV-1 replication and cure latent HIV-1 in the absence of drugs. Approaches that have been well studied are the anti-HIV-1 which targets RNAs, proteins, or peptides expressed by HIV-1 resistant cells, which can be transplanted to the patients. RNA interference in the form of small RNA has been proven as a promising therapy to prevent HIV-1 replication. It is utilized for therapy using cell transplantation and various gene combinations in clinical trials. However, many studies have been failed to show a successful eradication of latently HIV-1 infected T cells. It is happened due to the virus's ability to escape from antiviral therapies. However, this can be overcome by using a combination of ARTs. On the other hand, genetic editing has been intensively studied since it can cure various diseases caused by genetic or pathogen infections, including HIV type 1. The previous studies have designed gRNA bind to protein Cas type 9 targeting HIV functional genes, Tat and Rev sequences. Various recombination has been introduced to CRISPR-based gene editing to increase the binding affinity and efficiency of Cas9 to target Tat and Rev proteins of their exons. The best approach for the Cas9 targeted Tat and Rev is by utilizing more than one guide RNA. However, Subsequent studies are needed to confirm the ability of Cas9 with various guide RNAs to inhibit virus activation and replication in latent HIV-1. This review aims to describe the mechanisms, advantages, and disadvantages of antiviral therapies that target Tat and Rev as regulatory genes to eradicate latent HIV-1 infected T cells.
Background: Tuberculosis (TB) is one of most crucial public health issues around the world. TB is an entity of a complex disease with the socio-economic aspect that has very strong correlation in regard to combat this disease. Migration from developing country to developed country inevitably possesses big influence on global epidemiologic of TB. In Australia, TB still becomes the main threat not only in native population but also regarding the migrant movement into Australia. Indonesia is one of among the TB endemic countries with high TB cases, in which not merely due to its high TB prevalence and incidence but also influenced by very high and dense population. Aim: This literature aims to review the clinical, epidemiological, and microbiological aspects of tuberculosis as a comparison between developed country (Australia) and developing country (Indonesia). Conclusion:Tuberculosis cases in Australia remains low compared to Indonesia, however, the close proximity to adjacent developing countries with high endemic of TB contributes significantly to increase number of TB in Australia. Tuberculosis can be cured by following the treatment guidelines with proper monitoring. Moreover, the collaboration between public and private sector along with active collaboration from the family or people surrounding the patients is required to eliminate TB disease.
Ebola virus has resulted in a devastating hemorrhagic fever epidemic spanning several African countries and leading to thousands of deaths. There have been no vaccines approved or medication strategies toward successful prophylaxis and therapeutics critical until the rVSV-ZEBOV vaccine approved by the US Food and Drug Administration (FDA) in December 2019 as a preventative measure for people aged 18 years old and/or older. Several experimental vaccines are showing some promise. The most advanced vaccine is the clinically tested recombinant vesicular-stomatitis virus (rVSV) which encodes EBOV glycoprotein, widely known as the V920 vaccine candidate. This vaccine induces antibody-producing responses in non-human primate models, and current clinical trials suggest protective efficacy in humans. Although generally well-tolerated, the administration of this vaccine was complicated by occurrences of side effects. The development of vaccine platforms is also challenging, given that Ebola virus diseases have now reached epidemic proportions in some localities. Outcomes in terms of viral persistence after recovery are unknown, and a study explaining the role of adaptive immunity in recovery may be essential to inform effective vaccine design. This review aims to give a basic understanding on the general immunity mechanism elicited by recombinant vector vaccines and the current implementation of this relatively new technology to tackle a major infectious disease outbreak.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.